105 related articles for article (PubMed ID: 18727661)
1. Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy.
Sandrini S; Setti G; Bossini N; Maffei C; Iovinella L; Tognazzi N; Maffeis R; Nodari F; Portolani N; Cancarini G
Clin Transplant; 2009; 23(1):16-22. PubMed ID: 18727661
[TBL] [Abstract][Full Text] [Related]
2. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
3. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
Knight RJ; Villa M; Laskey R; Benavides C; Schoenberg L; Welsh M; Kerman RH; Podder H; Van Buren CT; Katz SM; Kahan BD
Clin Transplant; 2007; 21(4):460-5. PubMed ID: 17645704
[TBL] [Abstract][Full Text] [Related]
5. Early (fifth day) vs. late (sixth month) steroid withdrawal in renal transplant recipients treated with Neoral(®) plus Rapamune(®): four-yr results of a randomized monocenter study.
Sandrini S; Setti G; Bossini N; Chiappini R; Valerio F; Mazzola G; Maffeis R; Nodari F; Cancarini G
Clin Transplant; 2010; 24(5):669-77. PubMed ID: 20030684
[TBL] [Abstract][Full Text] [Related]
6. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
[TBL] [Abstract][Full Text] [Related]
7. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
8. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
[TBL] [Abstract][Full Text] [Related]
9. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
Legendre C; Brault Y; Morales JM; Oberbauer R; Altieri P; Riad H; Mahony J; Messina M; Pussell B; Martínez JG; Lelong M; Burke JT; Neylan JF;
Clin Transplant; 2007; 21(3):330-6. PubMed ID: 17488381
[TBL] [Abstract][Full Text] [Related]
11. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
12. New approaches to de novo immunosuppression and steroid elimination.
Lebranchu Y
Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
van Hooff JP; Squifflet JP; Wlodarczyk Z; Vanrenterghem Y; Paczek L
Transplantation; 2003 Jun; 75(12):1934-9. PubMed ID: 12829890
[TBL] [Abstract][Full Text] [Related]
14. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
Russ G; Jamieson N; Oberbauer R; Arias M; Murgia MG; Blancho G; Sato R; Stoeckl M; Revicki DA
Transpl Int; 2007 Oct; 20(10):875-83. PubMed ID: 17854445
[TBL] [Abstract][Full Text] [Related]
15. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
[TBL] [Abstract][Full Text] [Related]
18. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD
Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
